Laurie Stelzer - 22 Nov 2023 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Role
Director
Signature
/s/ Heidy King-Jones, as Attorney-in-Fact
Issuer symbol
SYRE
Transactions as of
22 Nov 2023
Net transactions value
$0
Form type
4
Filing time
27 Nov 2023, 16:33:03 UTC
Previous filing
10 Aug 2023
Next filing
16 May 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGLE Stock Option (Right to Buy) Award $0 +50,000 $0.000000 50,000 22 Nov 2023 Common Stock 50,000 $10.39 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase 50,000 shares of the Issuer's common stock, which will vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.